The Solve is a biopharmaceutical firm that develops and discovers chronic fatigue and immune dysfunction syndrome theraopies... Read more
Solve M.E. President & CEO: Emily Taylor

President & CEO

Emily Taylor

CEO Approval Rating

- -/100

Est. Annual Revenue
$100K-5.0M
Agree?
Est. Employees
25-100
Agree?

News

Jul 20, 2026
PR Newswire
Press Release: Solve M.E. : Solve M.E. Announces Catalyst Award Funding To Renegade Research For the Study of Therapeutic Devices for People with ME/CFS and Long Covid
Feb 24, 2026
StreetInsider
Press Release: Solve M.E. : Solve M.E. Funds GLP-1 and Immune Target Studies to Accelerate ME/CFS and Long Covid Breakthroughs
Aug 13, 2025
EIN Presswire
Press Release: Solve M.E. : Brain Inflammation Collaborative & Solve ME Launches Unified Platform to Advance Research Across 30+ Chronic Conditions
Jun 17, 2025
StreetInsider
Press Release: Solve M.E. : Solve M.E. Selects Simmaron Research As Recipient of ME/CFS Catalyst Award to Accelerate Low-Dose Rapamycin Trial for ME/CFS, Long COVID, and IACCs
Apr 08, 2024
Yahoo
Solve M.E.: Solve M.E. Announces Emily Taylor as New President and CEO and Publication of New White Paper Calling for NIH to Restructure Funding for ME/CFS, Long Covid, and other IACCIs
Oct 16, 2023
PR Newswire
Press Release: The Solve : Solve Appoints Kristin Jacobson as President and Chief Executive Officer
Dec 14, 2022
Markets Insider
The Solve: Solve M.E. Awarded Grant From Chan Zuckerberg Initiative to Support Patient Engagement in Long Covid Research
Aug 17, 2022
StreetInsider
Press Release: The Solve : SOLVE M.E. LAUNCHES THE FIRST NATIONWIDE PSA CAMPAIGN TO BROADEN AWARENESS OF LONG COVID
Jul 15, 2020
PR Newswire
Press Release: The Solve : Solve M.E. Announces Launch of You + M.E. Registry and Biobank to Transform the Study of ME/CFS and Post-viral, Chronic Illnesses Likely Impacted by COVID-19
Apr 21, 2020
PR Newswire
Press Release: The Chronic Fatigue and Immune Dysfunction Syndrome Association of America : As An Urgent COVID-19 Response, Advocates Implore Congress To Support Research Funding For Post-Viral Diseases--Specifically Myalgic Encephalomyelitis (ME)

Trending Companies